C E Teunissen


Affiliation: VU University Medical Center
Country: The Netherlands


  1. Koel Simmelink M, Vennegoor A, Killestein J, Blankenstein M, Norgren N, Korth C, et al. The impact of pre-analytical variables on the stability of neurofilament proteins in CSF, determined by a novel validated SinglePlex Luminex assay and ELISA. J Immunol Methods. 2014;402:43-9 pubmed publisher
    ..The newly developed NfH SinglePlex Luminex assay has a good sensitivity and is robust. Moreover, both NfH and NfL are stable under the most prevalent pre-analytical variations. ..
  2. Teunissen C, Koel Simmelink M, Pham T, Knol J, Khalil M, Trentini A, et al. Identification of biomarkers for diagnosis and progression of MS by MALDI-TOF mass spectrometry. Mult Scler. 2011;17:838-50 pubmed publisher
    ..286, p?<?0.028). Using high-throughput body fluid profiling by MALDI-TOF mass spectrometry, small proteins and peptides were detected as promising candidate biomarkers for diagnosis and disease progression of MS. ..
  3. Jahn N, Lamberts R, Busch C, Voelker M, Busch T, Koel Simmelink M, et al. Inhaled carbon monoxide protects time-dependently from loss of hypoxic pulmonary vasoconstriction in endotoxemic mice. Respir Res. 2015;16:119 pubmed publisher
    ..05). We found no effects on inflammatory plasma cytokines. Low-dose CO prevented LPS-induced impairment of HPV in a time-dependent manner, associated with a decreased NOS-2 expression. ..
  4. Aalten P, Ramakers I, Biessels G, De Deyn P, Koek H, Olderikkert M, et al. The Dutch Parelsnoer Institute--Neurodegenerative diseases; methods, design and baseline results. BMC Neurol. 2014;14:254 pubmed publisher
    ..The project has started with data analyses of the baseline characteristics and biomarkers, which will be the starting point of future specific research questions that can be answered by this unique dataset. ..
  5. Willemse E, Teunissen C. Biobanking of Cerebrospinal Fluid for Biomarker Analysis in Neurological Diseases. Adv Exp Med Biol. 2015;864:79-93 pubmed publisher
    ..The streamlining of biobanking procedures, including sample collection, quality control, and the selection of optimal control groups for investigating biomarkers is an important improvement to perform high quality biomarker studies. ..
  6. Chatterjee M, Del Campo M, Morrema T, de Waal M, van der Flier W, Hoozemans J, et al. Contactin-2, a synaptic and axonal protein, is reduced in cerebrospinal fluid and brain tissue in Alzheimer's disease. Alzheimers Res Ther. 2018;10:52 pubmed publisher
    ..Taken together, these data reveal that the contactin-2 changes observed in tissues are reflected in CSF, suggesting that decreased contactin-2 CSF levels might be a biomarker reflecting synaptic or axonal loss. ..
  7. Teunissen C, Petzold A, Bennett J, Berven F, Brundin L, Comabella M, et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology. 2009;73:1914-22 pubmed publisher
    ..We focus on CSF collection procedures, preanalytical factors, and high-quality clinical and paraclinical information. The biobanking protocols are applicable for CSF biobanks for research targeting any neurologic disease. ..
  8. Teunissen C, Durieux Lu S, Blankenstein M, Oude Voshaar R, Comijs H. The inflammatory marker GDF-15 is not independently associated with late-life depression. J Psychosom Res. 2016;83:46-9 pubmed publisher
    ..The inflammatory factor GDF-15 does not seem to be an independent inflammatory marker for late-life major depressive disorder. ..
  9. Malekzadeh A, Twaalfhoven H, Wijnstok N, Killestein J, Blankenstein M, Teunissen C. Comparison of multiplex platforms for cytokine assessments and their potential use for biomarker profiling in multiple sclerosis. Cytokine. 2017;91:145-152 pubmed publisher
    ..Overall, the increased levels of IL-6, IL-8 and TNF-α in serum of MS patients compared to healthy controls, support the use of multiple cytokines for future MS biomarker and disease progression research. ..

More Information


  1. Teunissen C, Otto M, Engelborghs S, Herukka S, Lehmann S, Lewczuk P, et al. White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation. Alzheimers Res Ther. 2018;10:30 pubmed publisher
    ..The society has a broad scope, as its vision is that the gaps in development and implementation of biomarkers are shared among almost all neurological diseases and thus they can benefit from the activities of the society. ..
  2. Ten Kate M, Barkhof F, Visser P, Teunissen C, Scheltens P, van der Flier W, et al. Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment. Alzheimers Res Ther. 2017;9:73 pubmed publisher
    ..The spatial pattern of decreased gray matter volume associated with progression to dementia was consistent for amyloid-positive and amyloid-negative subjects. ..
  3. Kester M, Teunissen C, Sutphen C, Herries E, Ladenson J, Xiong C, et al. Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort. Alzheimers Res Ther. 2015;7:59 pubmed publisher
    ..Increased levels of both YKL-40 and VILIP-1 may be associated with disease progression. These CSF biomarkers should be considered for future evaluation in the characterization of the natural history of AD. ..
  4. Teunissen C, Iacobaeus E, Khademi M, Brundin L, Norgren N, Koel Simmelink M, et al. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis. Neurology. 2009;72:1322-9 pubmed publisher
    ..Next, we wanted to know the additional value of measurement of NAA compared to other candidate markers for axonal damage, such as neurofilament subunits and tau protein...
  5. Teunissen C, Veerhuis R, de Vente J, Verhey F, Vreeling F, van Boxtel M, et al. Brain-specific fatty acid-binding protein is elevated in serum of patients with dementia-related diseases. Eur J Neurol. 2011;18:865-71 pubmed publisher
    ..In contrast to heart-type FABP, serum levels of brain-type FABP are elevated in a significant proportion of patients with various neurodegenerative diseases and can therefore have importance for defining subgroups of these patients. ..
  6. Bridel C, Hoffmann T, Meyer A, Durieux S, Koel Simmelink M, Orth M, et al. Glutaminyl cyclase activity correlates with levels of Aβ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer's disease patients. Alzheimers Res Ther. 2017;9:38 pubmed publisher
    ..The addition of QC activity to core diagnostic CSF biomarkers may be of specific interest in clinical cases with discordant imaging and biochemical biomarker results. ..
  7. Teunissen C, Verheul C, Willemse E. The use of cerebrospinal fluid in biomarker studies. Handb Clin Neurol. 2017;146:3-20 pubmed publisher